Vir Biotechnology: Cheap Near-Term Equity With Binary Upside from VIR-5500 and Licensing Deals
Vir (VIR) is trading around $8.79, a price that implies investors are paying only modestly above the company's reported cash cushion while giving little credit to upcoming clinical catalysts and recent partnership activity. For disciplined traders, a mid-term swing long offers asymmetric upside if VIR-5500 data and business development continue to …